Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...

While Novo Nordisk blamed rival drugs and its own tepid expansion for downgrades to sales and profit growth, some analysts ...

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors ...

The appointment came shortly after Novo slashed its financial forecast, predicting this year’s sales will grow 8% to 14%, ...

The firm also named Maziar Mike Doustdar as its new CEO on Tuesday, after a gloomy financial forecast spooked investors.View ...

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...